What's Happening?
C2N Diagnostics has announced the validation of its PrecivityAD2 blood test, which demonstrates high accuracy in detecting brain amyloid pathology in patients with mild cognitive impairment or dementia. The test showed 91% accuracy, 90% sensitivity, and 92% specificity compared to traditional amyloid PET imaging. Published in npj Dementia, the study confirms the test's reliability and aligns with expert recommendations for Alzheimer's diagnosis. The PrecivityAD2 test is available in most U.S. states and is expanding globally.
Why It's Important?
The PrecivityAD2 blood test offers a less invasive and more accessible method for diagnosing Alzheimer's disease, potentially improving early detection and treatment outcomes. As new disease-modifying therapies become available, accurate diagnosis is crucial for effective treatment. This advancement could enhance patient care and streamline clinical trials, contributing to the global effort to combat Alzheimer's disease.
What's Next?
C2N plans to expand the availability of the PrecivityAD2 test internationally, with ongoing collaborations with pharmaceutical companies and research institutions. The test's integration into clinical practice could lead to earlier intervention and better management of Alzheimer's disease, benefiting patients and healthcare systems worldwide.
